ADONIS
Aspirin Dose Optimized in Non-Cardioembolic Ischemic Stroke
|
Status:
Trial is ongoing with a projected enrollment of 2100 patients.
Purpose:
To determine the optimal dose of acetylsalicylic acid (ASA) that would minimize both the recurrence of noncardioembolic ischemic stroke and the risk of drug-related adverse events.
Design:
Double-blind, randomized, multicenter study.
Inclusion Criteria
Patients between the ages of 40 and 79 who present within 30 days of their first ischemic stroke are eligible for this study.
Exclusion Criteria
Pregnant females and persons who are obtunded or comatose at enrollment, who have a known contraindication to ASA, who have cardioembolic stroke or any condition requiring anticoagulation, whose strokes are suspected to be hemorrhagic, who concurrently use antiplatelets or coumadin, who are terminally ill, who are participating in another secondary prevention trial, or who are unable to comply with study protocol, will be excluded from this trial.
Patient Involvement:
Eligible patients will be randomized to receive 40, 80, 160, 325, 650, 975, or 1300 mg/day of ASA. They will be followed-up for two years.
Primary Outcome:
Recurrent stroke, MI, vascular death, serious adverse events at 2 years.
Source of Information:
Aspirin Dose Optimized in Non-Cardioembolic Ischemic Stroke (ADONIS). Presented at Ongoing Clinical Trials Session, 27th International Stroke Conference, Feb., 2002. [PDF Format]R Gan, ME Collantes, RD Jamora. Aspirin Dose Optimized in Ischemic Stroke. June 2004. World Congress of Neurology, Vancouver, Canada.
|
|
Web Links and Publications:
|
|
This information last updated on: 1/5/2009
Reviewed on: 07/16/2009.
|
Trials
Directories